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ABSTRACT
Objectives: Phosphodiesterase (PDE) III inhibitor therapy is
effective for treatment of acute decompensated heart failure
(ADHF). Nevertheless, this drug is expensive than conven-
tional inotropic agent dobutamine. We compared total medi-
cation costs of the patients treated with PDE III inhibitor
amrinone therapy to that of the patients treated with con-
ventional dobutamine therapy during initial hospitalization.
Methods: We analyzed 160 consecutive patients with ADHF
admitted to our hospital. Shock, dehydration, severe infec-
tion, multiple organ failure, and mild heart failure (New
York Heart Association class IIs) were not eligible for the
study. Ninety-seven patients were divided into two groups: 1)
DOB group treated with dobutamine therapy; and 2) AMR
group treated with amrinone therapy. Total medication costs
and cost for hospital room charge were calculated based on
their usage during the initial hospitalization for each patient.
Group comparison was done between the DOB and AMR
groups.
Results: Length of stay was longer in the DOB group than in
the AMR group. Mean calculated cost of intravenous drugs
was higher in the DOB group (173,186  239,147 yen) than
in the AMR group (63,145  47,223 yen, P < 0.05). Total
medication costs were higher in the DOB group than in the
AMR group. Cost for hospital room charge was higher in the
DOB group than in the AMR group.
Conclusions: In the treatment of ADHF, appropriate therapy
even with expensive drugs makes total medication costs less
expensive comparing with conventional therapy with cheaper
drugs during initial hospitalization.
Keywords: amrinone, dobutamine, heart failure, hospital
room charge, medication cost, phosphodiesterase II inhibitor.
Introduction
Intravenous inotropic agents are still on the ﬁrst-line
treatment for acute decompensated heart failure
(ADHF) in emergency departments in developed coun-
tries. Long-term use of inotropic agent dobutamine
was reported to deteriorate clinical course of ADHF
[1]. Recently, phosphodiesterase (PDE) III inhibitor
milrinone has been reported to fail to lower mortality
in acute heart failure [2]. Drug cost was higher for the
patients treated with milrinone than for the patients
treated with dobutamine because of higher price of
milrinone [3]. On the other hand, nesiritide is a prom-
ising brain-type natriuretic peptide for acute heart
failure. Despite of its higher price, nesiritide provided
lower mortality [4] and lower cost of treatment [5,6]
than milrinone did in the setting of ADHF. It is
explained by shortening of length of stay which is
realized by nesiritide’s appropriate therapeutic action
on ADHF [5,6].
Medical effects of amrinone for ADHF were already
published in previous journals [7–9]. We think PDE III
inhibitor amrinone has appropriate therapeutic action
on ADHF comparing with inotropic agent dobutamine,
though unit cost per dose of amrinone (49.11 yen/mg)
was higher than that of dobutamine (19.48 yen/mg).
We assumed that total medication costs of drugs might
be cheaper if we appropriately utilize costly drug for the
treatment of acute de-compensated heart failure. Thus,
we compared total medication costs during initial hos-
pitalization in the ADHF patients treated with
amrinone therapy to that in the patients treated with
dobutamine therapy in our hospital.
Methods
Patient Eligibility
We analyzed 160 consecutive patients with ADHF
admitted to our hospital from August 1995 to July
1998. Thirty-three patients were excluded from the
study because of shock (n = 5), dehydration (n = 20),
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severe infection (n = 6) and multiple organ failure
(n = 2). Then 30 patients with mild heart failure (New
York Heart Association [NYHA] class IIs) were
excluded. The remaining 97 patients (61 men and 36
women; mean age 65.2  10.8 years) with moderate
to severe heart failure (NYHA class IIm and III) were
enrolled in the study. The study procedures were in
accordance with the guidelines of our hospital, and
informed consent was obtained from each patient. We
arbitrarily allocated of the patients to dichotomized
regimens. There were two senior house ofﬁcers in
charge of patient care decision during the study period.
One (TS) always independently used amrinone (AMR)
and the other (HM) always independently used dob-
utamine (DOB). These two doctors took charges alter-
nately, and made dichotomized treatment groups.
Eventually, there were no differences in clinical back-
ground between the two groups except intravenous
regimens. We deﬁned the group treated with intrave-
nous DOB as the DOB group (n = 48). We deﬁned the
other group treated with intravenous AMR as the
AMR group (n = 49). We did not change the dose of
basal oral medications. As additional diuretics, we
used intravenous furosemide (30–660 mg/day) with
dobutamine in the DOB group. And we used intrave-
nous atrial natriuretic peptide (0.05–0.2 mg/kg/min)
with amrinone as additional diuretics in the AMR
group.
Cost Consequence Study
We conducted a cost consequence study from a hospi-
tal perspective. We manually collected each patient
data from his or her charts during the initial hospital-
ization. We calculated medical expenditure based on
the charts according to piecework payment system in
Japan during the study period. Japan has a system of
universal health coverage, whereby most of the popu-
lation is enrolled in some form of health insurance
scheme and are thus required to pay insurance premi-
ums. Fees for medical services are standardized nation-
wide by the Medical Fee Table and those for drugs by
the national health insurance (NHI) drug price list.
Health insurance provides reimbursement only for
those drugs listed in the NHI drug price list. Price list
for drugs and medical devices, and other medical pro-
cedures is determined by national government.
Cost of intravenous drugs was calculated based on
drug usage during the initial hospitalization for each
patient. Total medication cost including oral drugs and
cost for hospital room charge were also calculated
based on their usage during the initial hospitalization
for each patient. Average costs were determined for
each group. We compared those average costs and
length of stay between the DOB and AMR groups.
Intravenous drug prices were as follows: 1) furo-
semide 40 mg 1 ampule = 64 yen; 2) furosemide
100 mg 1 ampule = 223 yen; 3) dobutamine 100 mg
1 ampule = 1948 yen; 4) dobutamine 200 mg 1
vial = 3922 yen; 5) dobutamine 600 mg 1 vial = 8255
yen; 6) amrinone 50 mg 1 ampule = 2872 yen; 7)
amrinone 100 mg 1 ampule = 4911 yen; and 8) carp-
eritide 1000 mg 1 vial = 3344 yen.
Rates of hospital room charge were as follows: 1)
1651 yen/day (within 2 weeks); 2) 1420 yen/days (over
2 weeks and within 1 month): 3) 1215 yen/day (over
1 month and within 3 months); 4) 1127 yen/day
(over 3 months and within 6 months); and 5) 1095
yen/day (over 6 months).
Results were presented as mean  SD for continu-
ous variables. Data were statistically analyzed with
JMP statistical software (JMP version 5.1, SAS Insti-
tute, Cary, NC). Differences for continuous variables
were estimated by Wilcoxon signed-rank test (Mann–
Whitney U-test). Differences for categorical variables
were estimated by Fisher’s exact test or chi-square test,
as appropriate. A value of P < 0.05 was considered
signiﬁcant.
Results
Patient Characteristics
Age, sex, etiology of heart failure, and oral medication
were similar among the three groups (Table 1). Sever-
ity of heart failure, i.e., NYHA class was similar
between the DOB and AMR groups. Left ventricular
Table 1 Patient clinical background
DOB group AMR group
n 48 49
Age (years) 65.4 10.4 65.1 11.3
% Male 62.5% 63.3%
Etiology
Hypertensive heart disease 13 (27.1%) 14 (28.6%)
Valvular heart disease 15 (31.2%) 15 (30.6%)
Ischemic heart disease 8 (16.7%) 7 (14.3%)
Cardiomyopathy 12 (25.0%) 13 (26.5%)
NYHA class (IIm/III) 17/31 12/37
LVEF 31.6 15.5% 31.3 14.8%
Oral medications
Digitalis 25 (52.1%) 27 (55.1%)
ACEI 32 (66.7%) 31 (63.3%)
Captopril 20 (41.7%) 18 (36.7%)
Enalapril 12 (25.0%) 11 (22.4%)
Beta-blocker 7 (14.6%) 6 (12.2%)
Propranolol 3 (6.3%) 3 (6.1%)
Metoprolol 4 (8.3%) 3 (6.1%)
Diuretics 48 (100%) 49 (100%)
Furosemide 41 (85.4%) 41 (83.7%)
Spironolactone 29 (60.4%) 27 (55.1%)
Nitrate 7 (14.6%) 9 (18.4%)
ISDN 6 (12.5%) 8 (16.3%)
ISMN 1 (2.1%) 1 (2.0%)
Calcium channel blocker 10 (20.8%) 12 (24.5%)
Nifedipine 7 (14.6%) 9 (18.4%)
Diltiazem 3 (6.3%) 3 (6.1%)
ACEI, angiotensin converting enzyme inhibitor; AMR, amrinone; DOB, dobutamine;
ISDN, isosorbide dinitrate; ISMN, isosorbide mononitrate; LVEF, left ventricular ejec-
tion fraction; NHYA, NewYork Heart Association.
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ejection fraction (LVEF) determined by echocardio-
graphy on admission was also similar between the
DOB and AMR groups.
Length of Stay and Cost of Drugs
Mean length of stay for initial hospitalization was
27.6  31.9 days in the DOB group and 6.1 
4.2 days in the AMR group. Length of stay was longer
in the DOB group than in the AMR group (Fig. 1a).
Mean accumulated doses of intravenous drugs were
8868  12,233 mg of dobutamine and 199  379 mg
of furosemide in the DOB group, and 3210 
2399 mg of amrinone and 471  352 mg of hANP in
the AMR group. Mean calculated cost of intravenous
drugs was higher in the DOB group (173,186 
239,147 yen) than in the AMR group (63,145 
47,223 yen, P < 0.05) (Fig. 1b). Total medication cost
was higher in the DOB group (186,599  238,903
yen) than in the AMR group (73,335  46,327 yen,
P < 0.05) (Fig. 1c). Cost for hospital room charge was
higher in the DOB group (64,215  44,963 yen) than
in the AMR group (32,951  12,495 yen, P < 0.05)
(Fig. 1d).
Adverse Events
Although minor adverse events including renal dys-
function (elevation in serum creatinine more than
1.5 mg/dL and less than 3.0 mg/dL) (nine patients in
DOB, one patient in AMR), serum Na lowering (three
patients in DOB, one patient in AMR), and nonsus-
tained ventricular tachycardia (one patient in DOB, 0
in AMR) were observed in the clinical course; all of
those events were reversible. Nevertheless, event rate
of renal dysfunction was higher in the DOB group than
in the AMR group (P < 0.001). In this study, all the
patients were able to be discharged and no patient
died.
Discussion
Patient Background
Our results suggested that expensive amrinone therapy
resulted in inexpensive cost of drugs and cost of hos-
pital stay relative to conventional dobutamine therapy.
On the contrary, Yamani et al. reported that treatment
of ADHF with milrinone was expensive compared to
that with dobutamine [3]. In their study, subjects were
sicker patients including NYHA class IV and lower
mean LVEF of 18% [3]. Then, milrinone did not
shorten the length of stay, and the treatment with
milrinone became expensive [3]. Our subjects were less
sick patients with class IIm or III and mean LVEF of
32%. Therefore, in-hospital mortality was 9% in their
study, while that was 0% in our study. Differences in
the seriousness of the subjects might affect the differ-
ences in the outcome and hence the differences in costs.
Aranda et al. also reported that milrinone therapy for
severely ill patients did not shorten length of stay as
compared to dobutamine, although in-hospital mortal-
ity was similarly low in both treatments [10]. Thus,
total medication cost of the milrinone group was
higher than that of the dobutamine group [10].
Levinoff Roth et al. found amrinone was effective
for refractory heart failure (NYHA class III and IV)
patients [11]. Nevertheless, they compared intrave-
nous amrinone with conventional oral therapy.
Amrinone may be more cost-effective in severer
patients (NYHA class IV). Nevertheless, we only ana-
sgurDsuonevartnIfotsoCyatSfohtgneL
egrahCmooRlatipsoHsgurDllAfotsoC
a.
d.
b.
c.
DOB AMR
0
10
20
30
40
50
60
70
(Days)
*
DOB AMR
0
50,000
100,000
150,000
200,000
250,000
300,000
350,000
400,000
450,000
(yen)
*
DOB AMR
0
50,000
100,000
150,000
200,000
250,000
300,000
350,000
400,000
450,000
(yen)
*
DOB AMR
0
20,000
40,000
60,000
80,000
100,000
120,000
(yen)
*
Figure 1 (a) Length of stay was longer in the
DOB group than in the AMR group (*P < 0.05);
(b) Mean calculated cost of intravenous drugs
was higher in the DOB group than in the AMR
group (*P < 0.05); (c) Total medication cost was
higher in the DOB group than in theAMR group
(*P < 0.05); (d) Cost for hospital room charge
was higher in the DOB group than in the
AMR group (*P < 0.05). AMR, amrinone; DOB,
dobutamine.
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lyzed class IIm and III patients in the present study.
Taken together, we need a prospective randomized
controlled study to ﬁnd out whether amrinone therapy
is more cost-effective than dopamine in the treatment
of terminally severe heart failure patients.
Limitations
As mentioned above, this study did not involve severer
patients. Thus, we did not experience the extension of
length of stay because of deterioration of heart failure.
And hence, we did not experienced major adverse
effects of amrinone, i.e., sustained ventricular tachy-
cardia or hypotension.
We only analyzed the cost for initial hospitalization
and did not include cost for rehospitalization. If we
calculated the costs for drugs or hospitalization for a
certain ﬁxed period like 1 or 2 years after the admis-
sion, cost for amrinone therapy might have changed.
This is not a prospective randomized controlled
trial. Although, the study patients had similar oral
medications and clinical background, we cannot deny
a selection bias in the study background. It was tre-
mendously difﬁcult to conduct a randomized con-
trolled cost comparison in the study period, because
we did not have sophisticated online payment database
system in Japan.
Recently, Diagnosis Procedure Combination, a
Japanese version of Diagnostic Related Groups-based
Prospective Payment System has become widespread
and commonly used in Japanese hospitals. According
to this new precision system, the cost for hospital stay
might be different from the present conclusion.
Nevertheless, favorable effects of amrinone on clinical
courses of moderately to severely ill patients could
shorten the length of stay and could lessen acquisition
cost of amrinone even in the new payment system.
Conclusion
Amrinone therapy shortened length of stay in a sub-
group of the Japanese patients with ADHF compared
to that in the patients treated with conventional dob-
utamine therapy. In this study, total medication cost
and cost for hospital room charge were relatively inex-
pensive in the patients treated with amrinone therapy
as compared to those treated with dobutamine therapy
in spite of higher prices of amrinone treatment. In the
treatment of ADHF, appropriate therapy even with
expensive drugs makes total medication costs less
expensive comparing with conventional therapy with
cheaper drugs during initial hospitalization.
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